-
2
-
-
32544432029
-
Non-motor symptoms of Parkinson's disease: Diagnosis and management
-
Chaudhuri KR, Healy DG, Schapira AH. Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol 2006;5:235-45
-
(2006)
Lancet Neurol
, vol.5
, pp. 235-245
-
-
Chaudhuri, K.R.1
Healy, D.G.2
Schapira, A.H.3
-
3
-
-
0034719073
-
Complications and limitations of drug therapy for Parkinson's disease
-
Jankovic J. Complications and limitations of drug therapy for Parkinson's disease. Neurology 2000;55:S2-6
-
(2000)
Neurology
, vol.55
-
-
Jankovic, J.1
-
4
-
-
1942520420
-
Challenges in Parkinson's disease: Restoration of the nigrostriatal dopamine system is not enough
-
Lang AE, Obeso JA. Challenges in Parkinson's disease: restoration of the nigrostriatal dopamine system is not enough. Lancet Neurol 2004;3:309-16
-
(2004)
Lancet Neurol
, vol.3
, pp. 309-316
-
-
Lang, A.E.1
Obeso, J.A.2
-
5
-
-
14944354884
-
Sydney Multicenter Study of Parkinson's disease: Non-L-dopa-responsive problems dominate at 15 years
-
Hely MA, Morris JG, Reid WG, Trafficante R. Sydney Multicenter Study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years. Mov Disord 2005;20:190-9
-
(2005)
Mov Disord
, vol.20
, pp. 190-199
-
-
Hely, M.A.1
Morris, J.G.2
Reid, W.G.3
Trafficante, R.4
-
6
-
-
0014082977
-
Parkinsonism: Onset, progression and mortality
-
Hoehn MM, Yahr MD. Parkinsonism: onset, progression and mortality. Neurology 1967;17:427-42
-
(1967)
Neurology
, vol.17
, pp. 427-442
-
-
Hoehn, M.M.1
Yahr, M.D.2
-
7
-
-
4644321549
-
Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: Status and recommendations
-
Goetz CG, Poewe W, Rascal O, et al. Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations. Mov Disord 2004;19:1020-8
-
(2004)
Mov Disord
, vol.19
, pp. 1020-1028
-
-
Goetz, C.G.1
Poewe, W.2
Rascal, O.3
-
8
-
-
20544468414
-
Nonmotor complications in Parkinson's disease
-
Adler CH. Nonmotor complications in Parkinson's disease. Mov Disord 2005;20(Suppl 11):S23-9
-
(2005)
Mov Disord
, vol.20
, Issue.SUPPL. 11
-
-
Adler, C.H.1
-
9
-
-
0027302579
-
Mortality from Parkinson's disease in England and Wales 1921-89
-
Clarke CE. Mortality from Parkinson's disease in England and Wales 1921-89. J Neurol Neurosurg Psychiatry 1993;56:690-3
-
(1993)
J Neurol Neurosurg Psychiatry
, vol.56
, pp. 690-693
-
-
Clarke, C.E.1
-
10
-
-
0031667288
-
The natural history of Parkinson's disease
-
Poewe WH, Wenning GK. The natural history of Parkinson's disease. Ann Neurol 1998;44:S1-9
-
(1998)
Ann Neurol
, vol.44
-
-
Poewe, W.H.1
Wenning, G.K.2
-
11
-
-
34548282615
-
Apomorphine in the treatment of Parkinson's disease
-
Menon R, Stacy M. Apomorphine in the treatment of Parkinson's disease. Expert Opin Pharmacother 2007;8:1941-50
-
(2007)
Expert Opin Pharmacother
, vol.8
, pp. 1941-1950
-
-
Menon, R.1
Stacy, M.2
-
12
-
-
34547191858
-
Medical management of levodopa-associated motor complications in patients with Parkinson's disease
-
Jankovic J, Stacy M. Medical management of levodopa-associated motor complications in patients with Parkinson's disease. CNS Drugs 2007;21:677-92
-
(2007)
CNS Drugs
, vol.21
, pp. 677-692
-
-
Jankovic, J.1
Stacy, M.2
-
14
-
-
33845409358
-
Criteria for deep-brain stimulation in Parkinson's disease: Review and analysis
-
Moro E, Lang AE. Criteria for deep-brain stimulation in Parkinson's disease: review and analysis. Expert Rev Neurother 2006;6:1695-705
-
(2006)
Expert Rev Neurother
, vol.6
, pp. 1695-1705
-
-
Moro, E.1
Lang, A.E.2
-
15
-
-
34047239617
-
Duodenal levodopa infusion for the treatment of Parkinson's disease
-
Samanta J, Hauser RA. Duodenal levodopa infusion for the treatment of Parkinson's disease. Expert Opin Pharmacother 2007;8:657-64
-
(2007)
Expert Opin Pharmacother
, vol.8
, pp. 657-664
-
-
Samanta, J.1
Hauser, R.A.2
-
16
-
-
33646107153
-
Practice parameter: Evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology
-
Miyasaki JM, Shannon K, Voon V, et al. Practice parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006;66:996-1002
-
(2006)
Neurology
, vol.66
, pp. 996-1002
-
-
Miyasaki, J.M.1
Shannon, K.2
Voon, V.3
-
17
-
-
10044283107
-
Rivastigmine for dementia associated with Parkinson's disease
-
Emre M, Aarsland D, Albanese A, et al. Rivastigmine for dementia associated with Parkinson's disease. N Engl J Med 2004;351:2509-18
-
(2004)
N Engl J Med
, vol.351
, pp. 2509-2518
-
-
Emre, M.1
Aarsland, D.2
Albanese, A.3
-
18
-
-
33646256562
-
Long-term benefits of rivastigmine in dementia associated with Parkinson's disease: An active treatment extension study
-
Poewe W, Wolters E, Emre M, et al. Long-term benefits of rivastigmine in dementia associated with Parkinson's disease: an active treatment extension study. Mov Disord 2006;21:456-61
-
(2006)
Mov Disord
, vol.21
, pp. 456-461
-
-
Poewe, W.1
Wolters, E.2
Emre, M.3
-
19
-
-
21344444811
-
Donepezil for dementia in Parkinson's disease: A randomised, double blind, placebo controlled, crossover study
-
Ravina B, Putt M, Siderowf A, et al. Donepezil for dementia in Parkinson's disease: a randomised, double blind, placebo controlled, crossover study. J Neurol Neurosurg Psychiatry 2005;76:934-9
-
(2005)
J Neurol Neurosurg Psychiatry
, vol.76
, pp. 934-939
-
-
Ravina, B.1
Putt, M.2
Siderowf, A.3
-
20
-
-
0036265213
-
Donepezil for cognitive impairment in Parkinson's disease: A randomised controlled study
-
Aarsland D, Laake K, Larsen JP, Janvin C. Donepezil for cognitive impairment in Parkinson's disease: a randomised controlled study. J Neurol Neurosurg Psychiatry 2002;72:708-12
-
(2002)
J Neurol Neurosurg Psychiatry
, vol.72
, pp. 708-712
-
-
Aarsland, D.1
Laake, K.2
Larsen, J.P.3
Janvin, C.4
-
21
-
-
0842325101
-
Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkinson's disease
-
Leroi I, Brandt J, Reich SG, et al. Randomized placebo-controlled trial of donepezil in cognitive impairment in Parkinson's disease. Int J Geriatr Psychiatry 2004;19:1-8
-
(2004)
Int J Geriatr Psychiatry
, vol.19
, pp. 1-8
-
-
Leroi, I.1
Brandt, J.2
Reich, S.G.3
-
22
-
-
0034718471
-
Olanzapine and clozapine: Comparative effects on motor function in hallucinating Parkinson's disease patients
-
Goetz CG, Blasucci LM, Leurgans S, Pappert EJ. Olanzapine and clozapine: comparative effects on motor function in hallucinating Parkinson's disease patients. Neurology 2000;55:789-94
-
(2000)
Neurology
, vol.55
, pp. 789-794
-
-
Goetz, C.G.1
Blasucci, L.M.2
Leurgans, S.3
Pappert, E.J.4
-
23
-
-
0033709683
-
Risperidone in the treatment of dopamine-induced psychosis in Parkinson's disease: An open pilot trial
-
Mohr E, Mendis T, Hildebrand K, De Deyn PP. Risperidone in the treatment of dopamine-induced psychosis in Parkinson's disease: an open pilot trial. Mov Disord 2000;15:1230-7
-
(2000)
Mov Disord
, vol.15
, pp. 1230-1237
-
-
Mohr, E.1
Mendis, T.2
Hildebrand, K.3
De Deyn, P.P.4
-
24
-
-
0034022838
-
Risperidone treatment of drug-related psychosis in patients with parkinsonism
-
Leopold NA. Risperidone treatment of drug-related psychosis in patients with parkinsonism. Mov Disord 2000;15:301-4
-
(2000)
Mov Disord
, vol.15
, pp. 301-304
-
-
Leopold, N.A.1
-
25
-
-
33846116654
-
Treatment of drug-induced psychosis in Parkinson's disease with ziprasidone can induce severe dose-dependent off-periods and pathological laughing
-
Schindehutte J, Trenkwalder C. Treatment of drug-induced psychosis in Parkinson's disease with ziprasidone can induce severe dose-dependent off-periods and pathological laughing. Clin Neurol Neurosurg 2007;109:188-91
-
(2007)
Clin Neurol Neurosurg
, vol.109
, pp. 188-191
-
-
Schindehutte, J.1
Trenkwalder, C.2
-
28
-
-
33846447413
-
Open-label flexible-dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease
-
Friedman JH, Berman RM, Goetz CG, et al. Open-label flexible-dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease. Mov Disord 2006;21:2078-81
-
(2006)
Mov Disord
, vol.21
, pp. 2078-2081
-
-
Friedman, J.H.1
Berman, R.M.2
Goetz, C.G.3
-
29
-
-
1442300056
-
Aripiprazole for drug-induced psychosis in Parkinson disease: Preliminary experience
-
Fernandez HH, Trieschmann ME, Friedman JH. Aripiprazole for drug-induced psychosis in Parkinson disease: preliminary experience. Clin Neuropharmacol 2004;27:4-5
-
(2004)
Clin Neuropharmacol
, vol.27
, pp. 4-5
-
-
Fernandez, H.H.1
Trieschmann, M.E.2
Friedman, J.H.3
-
30
-
-
33750369930
-
Aripiprazole associated with severe exacerbation of Parkinson's disease
-
Wickremaratchi M, Morris HR, Ali IM. Aripiprazole associated with severe exacerbation of Parkinson's disease. Mov Disord 2006;21:1538-9
-
(2006)
Mov Disord
, vol.21
, pp. 1538-1539
-
-
Wickremaratchi, M.1
Morris, H.R.2
Ali, I.M.3
-
31
-
-
0033545542
-
Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease
-
The Parkinson Study Group
-
The Parkinson Study Group. Low-dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease. N Engl J Med 1999;340:757-63
-
(1999)
N Engl J Med
, vol.340
, pp. 757-763
-
-
-
32
-
-
1942421734
-
Clozapine in drug induced psychosis in Parkinson's disease: A randomised, placebo controlled study with open follow up
-
Pollak P, Tison F, Rascol O, et al. Clozapine in drug induced psychosis in Parkinson's disease: a randomised, placebo controlled study with open follow up. J Neurol Neurosurg Psychiatry 2004;75:689-95
-
(2004)
J Neurol Neurosurg Psychiatry
, vol.75
, pp. 689-695
-
-
Pollak, P.1
Tison, F.2
Rascol, O.3
-
33
-
-
33846074353
-
Clozapine-associated myocarditis: A review of 116 cases of suspected myocarditis associated with the use of clozapine in Australia during 1993-2003
-
Haas SJ, Hill R, Krum H, et al. Clozapine-associated myocarditis: a review of 116 cases of suspected myocarditis associated with the use of clozapine in Australia during 1993-2003. Drug Saf 2007;30:47-57
-
(2007)
Drug Saf
, vol.30
, pp. 47-57
-
-
Haas, S.J.1
Hill, R.2
Krum, H.3
-
35
-
-
11144267254
-
Clozapine-related myocarditis and cardiomyopathy in an Australian metropolitan psychiatric service
-
Reinders J, Parsonage W, Lange D, et al. Clozapine-related myocarditis and cardiomyopathy in an Australian metropolitan psychiatric service. Aust NZ J Psychiatry 2004;38:915-22
-
(2004)
Aust NZ J Psychiatry
, vol.38
, pp. 915-922
-
-
Reinders, J.1
Parsonage, W.2
Lange, D.3
-
36
-
-
3343000099
-
Clozapine-induced acute interstitial nephritis
-
Au AF, Luthra V, Stern R. Clozapine-induced acute interstitial nephritis. Am J Psychiatry 2004;161:1501
-
(2004)
Am J Psychiatry
, vol.161
, pp. 1501
-
-
Au, A.F.1
Luthra, V.2
Stern, R.3
-
37
-
-
0033517566
-
Clozapine-induced acute interstitial nephritis
-
Elias TJ, Bannister KM, Clarkson AR, et al. Clozapine-induced acute interstitial nephritis. Lancet 1999;354:1180-1
-
(1999)
Lancet
, vol.354
, pp. 1180-1181
-
-
Elias, T.J.1
Bannister, K.M.2
Clarkson, A.R.3
-
38
-
-
0343133914
-
Association of venous thromboembolism and clozapine
-
Hagg S, Spigset O, Soderstrom TG. Association of venous thromboembolism and clozapine. Lancet 2000;355:1155-6
-
(2000)
Lancet
, vol.355
, pp. 1155-1156
-
-
Hagg, S.1
Spigset, O.2
Soderstrom, T.G.3
-
39
-
-
26444597010
-
Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson's disease
-
Ondo WG, Tintner R, Voung KD, et al. Double-blind, placebo-controlled, unforced titration parallel trial of quetiapine for dopaminergic-induced hallucinations in Parkinson's disease. Mov Disord 2005;20:958-63
-
(2005)
Mov Disord
, vol.20
, pp. 958-963
-
-
Ondo, W.G.1
Tintner, R.2
Voung, K.D.3
-
40
-
-
34147140466
-
Effect of quetiapine in psychotic Parkinson's disease patients: A double-blind labeled study of 3 months' duration
-
Rabey JM, Prokhorov T, Miniovitz A, et al. Effect of quetiapine in psychotic Parkinson's disease patients: a double-blind labeled study of 3 months' duration. Mov Disord 2007;22:313-8
-
(2007)
Mov Disord
, vol.22
, pp. 313-318
-
-
Rabey, J.M.1
Prokhorov, T.2
Miniovitz, A.3
-
41
-
-
4043113047
-
Falls and freezing of gait in Parkinson's disease: A review of two interconnected, episodic phenomena
-
Bloem BR, Hausdorff JM, Visser JE, Giladi N. Falls and freezing of gait in Parkinson's disease: a review of two interconnected, episodic phenomena. Mov Disord 2004;19:871-84
-
(2004)
Mov Disord
, vol.19
, pp. 871-884
-
-
Bloem, B.R.1
Hausdorff, J.M.2
Visser, J.E.3
Giladi, N.4
-
42
-
-
0037018742
-
Treatment interventions for Parkinson's disease: An evidence based assessment
-
Rascol O, Goetz C, Koller W, et al. Treatment interventions for Parkinson's disease: an evidence based assessment. Lancet 2002;359:1589-98
-
(2002)
Lancet
, vol.359
, pp. 1589-1598
-
-
Rascol, O.1
Goetz, C.2
Koller, W.3
-
43
-
-
0035225781
-
Physiotherapy for patients with Parkinson's disease: A comparison of techniques
-
CD002817
-
Deane KH, Jones D, Playford ED, et al. Physiotherapy for patients with Parkinson's disease: a comparison of techniques. Cochrane Database Syst Rev 2001:CD002817
-
(2001)
Cochrane Database Syst Rev
-
-
Deane, K.H.1
Jones, D.2
Playford, E.D.3
-
44
-
-
33646104205
-
Practice parameter: Neuroprotective strategies and alternative therapies for Parkinson disease (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology
-
Suchowersky O, Gronseth G, Perlmutter J, et al. Practice parameter: neuroprotective strategies and alternative therapies for Parkinson disease (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006;66:976-82
-
(2006)
Neurology
, vol.66
, pp. 976-982
-
-
Suchowersky, O.1
Gronseth, G.2
Perlmutter, J.3
-
45
-
-
33846873850
-
Cueing training in the home improves gait-related mobility in Parkinson's disease: The RESCUE trial
-
Nieuwboer A, Kwakkel G, Rochester L, et al. Cueing training in the home improves gait-related mobility in Parkinson's disease: the RESCUE trial. J Neurol Neurosurg Psychiatry 2007;78:134-40
-
(2007)
J Neurol Neurosurg Psychiatry
, vol.78
, pp. 134-140
-
-
Nieuwboer, A.1
Kwakkel, G.2
Rochester, L.3
-
46
-
-
30644456332
-
Gait and step training to reduce falls in Parkinson's disease
-
Protas EJ, Mitchell K, Williams A, et al. Gait and step training to reduce falls in Parkinson's disease. NeuroRehabilitation 2005;20:183-90
-
(2005)
NeuroRehabilitation
, vol.20
, pp. 183-190
-
-
Protas, E.J.1
Mitchell, K.2
Williams, A.3
-
48
-
-
33746931673
-
2 for prevention of hip fracture in Parkinson's disease: A randomized controlled trial
-
2 for prevention of hip fracture in Parkinson's disease: a randomized controlled trial. Mov Disord 2006;21:924-9
-
(2006)
Mov Disord
, vol.21
, pp. 924-929
-
-
Sato, Y.1
Iwamoto, J.2
Kanoko, T.3
Satoh, K.4
-
49
-
-
34147108671
-
Risedronate and ergocalciferol prevent hip fracture in elderly men with Parkinson disease
-
Sato Y, Honda Y, Iwamoto J. Risedronate and ergocalciferol prevent hip fracture in elderly men with Parkinson disease. Neurology 2007;68:911-5
-
(2007)
Neurology
, vol.68
, pp. 911-915
-
-
Sato, Y.1
Honda, Y.2
Iwamoto, J.3
-
51
-
-
33845187834
-
Joint and skeletal deformities in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy
-
Ashour R, Jankovic J. Joint and skeletal deformities in Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Mov Disord 2006;21:1856-63
-
(2006)
Mov Disord
, vol.21
, pp. 1856-1863
-
-
Ashour, R.1
Jankovic, J.2
-
52
-
-
34548460736
-
The effect of duloxetine on primary pain symptoms in Parkinson disease
-
Djaldetti R, Yust-Katz S, Kolianov V, et al. The effect of duloxetine on primary pain symptoms in Parkinson disease. Clin Neuropharmacol 2007;30:201-5
-
(2007)
Clin Neuropharmacol
, vol.30
, pp. 201-205
-
-
Djaldetti, R.1
Yust-Katz, S.2
Kolianov, V.3
-
53
-
-
29244432154
-
-
Dias R, Cutts S, Massoud S. Frozen shoulder. BMJ 2005;331:1453-6
-
Dias R, Cutts S, Massoud S. Frozen shoulder. BMJ 2005;331:1453-6
-
-
-
-
55
-
-
29744440474
-
-
Drake DF, Harkins S, Qutubuddin A. Pain in Parkinson's disease: pathology to treatment, medication to deep brain stimulation. NeuroRehabilitation 2005;20:335-41
-
Drake DF, Harkins S, Qutubuddin A. Pain in Parkinson's disease: pathology to treatment, medication to deep brain stimulation. NeuroRehabilitation 2005;20:335-41
-
-
-
-
57
-
-
84882535310
-
-
Stocchi F. Gastrointestinal, urological. and sleep problems in Parkinson's disease. In: Principles of Treatment in Parkinson's Disease. Schapira AHV, Olanow CW, editors. Philadelphia: Butterworth Heinemann; 2005 p. 251-75
-
Stocchi F. Gastrointestinal, urological. and sleep problems in Parkinson's disease. In: Principles of Treatment in Parkinson's Disease. Schapira AHV, Olanow CW, editors. Philadelphia: Butterworth Heinemann; 2005 p. 251-75
-
-
-
-
58
-
-
0022575682
-
Swallowing and speech production in Parkinson's disease
-
Robbins JA, Logemann JA, Kirshner HS. Swallowing and speech production in Parkinson's disease. Ann Neurol 1986;19:283-7
-
(1986)
Ann Neurol
, vol.19
, pp. 283-287
-
-
Robbins, J.A.1
Logemann, J.A.2
Kirshner, H.S.3
-
59
-
-
0036765130
-
Systematic review of paramedical therapies for Parkinson's disease
-
Deane KH, Ellis-Hill C, Jones D, et al. Systematic review of paramedical therapies for Parkinson's disease. Mov Disord 2002;17:984-91
-
(2002)
Mov Disord
, vol.17
, pp. 984-991
-
-
Deane, K.H.1
Ellis-Hill, C.2
Jones, D.3
-
61
-
-
33646925831
-
Botulinum toxin type A for drooling in Parkinson's disease: A double-blind, randomized, placebo-controlled study
-
Lagalla G, Millevolte M, Capecci M, et al. Botulinum toxin type A for drooling in Parkinson's disease: a double-blind, randomized, placebo-controlled study. Mov Disord 2006;21:704-7
-
(2006)
Mov Disord
, vol.21
, pp. 704-707
-
-
Lagalla, G.1
Millevolte, M.2
Capecci, M.3
-
62
-
-
0242662829
-
A randomized trial of botulinum toxin A for treatment of drooling
-
Lipp A, Trottenberg T, Schink T, et al. A randomized trial of botulinum toxin A for treatment of drooling. Neurology 2003;61:1279-81
-
(2003)
Neurology
, vol.61
, pp. 1279-1281
-
-
Lipp, A.1
Trottenberg, T.2
Schink, T.3
-
63
-
-
0033974106
-
Botulinum toxin A as treatment for drooling saliva in PD
-
Pal PK, Calne DB, Calne S, Tsui JK. Botulinum toxin A as treatment for drooling saliva in PD. Neurology 2000;54:244-7
-
(2000)
Neurology
, vol.54
, pp. 244-247
-
-
Pal, P.K.1
Calne, D.B.2
Calne, S.3
Tsui, J.K.4
-
65
-
-
0000442521
-
Quantitative assessment of parkinsonian sialorrhea and results of treatment with botulinum toxin
-
Friedman A, Potulska A. Quantitative assessment of parkinsonian sialorrhea and results of treatment with botulinum toxin. Parkinsonism Relat Disord 2001;7:329-32
-
(2001)
Parkinsonism Relat Disord
, vol.7
, pp. 329-332
-
-
Friedman, A.1
Potulska, A.2
-
66
-
-
1542315511
-
Ultrasound-guided versus 'blind' intraparotid injections of botulinum toxin-A for the treatment of sialorrhoea in patients with Parkinson's disease
-
Dogu O, Apaydin D, Sevim S, et al. Ultrasound-guided versus 'blind' intraparotid injections of botulinum toxin-A for the treatment of sialorrhoea in patients with Parkinson's disease. Clin Neurol Neurosurg 2004;106:93-6
-
(2004)
Clin Neurol Neurosurg
, vol.106
, pp. 93-96
-
-
Dogu, O.1
Apaydin, D.2
Sevim, S.3
-
67
-
-
0345830743
-
A double-blind placebo-controlled trial of botulinum toxin B for sialorrhea in Parkinson's disease
-
Ondo WG, Hunter C, Moore W. A double-blind placebo-controlled trial of botulinum toxin B for sialorrhea in Parkinson's disease. Neurology 2004;62:37-40
-
(2004)
Neurology
, vol.62
, pp. 37-40
-
-
Ondo, W.G.1
Hunter, C.2
Moore, W.3
-
68
-
-
38049053597
-
Ipratropium bromide spray as treatment for sialorrhea in Parkinson's disease
-
Thomsen TR, Galpern WR, Asante A, et al. Ipratropium bromide spray as treatment for sialorrhea in Parkinson's disease. Mov Disord 2007;22:2268-73
-
(2007)
Mov Disord
, vol.22
, pp. 2268-2273
-
-
Thomsen, T.R.1
Galpern, W.R.2
Asante, A.3
-
69
-
-
33846811509
-
Tegaserod in constipation associated with Parkinson disease
-
Morgan JC, Sethi KD. Tegaserod in constipation associated with Parkinson disease. Clin Neuropharmacol 2007;30:52-4
-
(2007)
Clin Neuropharmacol
, vol.30
, pp. 52-54
-
-
Morgan, J.C.1
Sethi, K.D.2
-
70
-
-
34548272597
-
Macrogol for the treatment of constipation in Parkinson's disease. A randomized placebo-controlled study
-
Zangaglia R, Martignoni E, Glorioso M, et al. Macrogol for the treatment of constipation in Parkinson's disease. A randomized placebo-controlled study. Mov Disord 2007;22:1239-44
-
(2007)
Mov Disord
, vol.22
, pp. 1239-1244
-
-
Zangaglia, R.1
Martignoni, E.2
Glorioso, M.3
-
71
-
-
33745847810
-
Bladder dysfunction in parkinsonism: Mechanisms, prevalence, symptoms, and management
-
Winge K, Fowler CJ. Bladder dysfunction in parkinsonism: mechanisms, prevalence, symptoms, and management. Mov Disord 2006;21:737-45
-
(2006)
Mov Disord
, vol.21
, pp. 737-745
-
-
Winge, K.1
Fowler, C.J.2
-
72
-
-
41149107709
-
Depression, psychosis, and cognitive dysfunction in Parkinson's disease
-
Schapira AHV, Olanow CW, editors. Philadelphia Butterworth Heinemann;
-
Stocchi F. Depression, psychosis, and cognitive dysfunction in Parkinson's disease. In: Principles of Treatment in Parkinson's Disease. Schapira AHV, Olanow CW, editors. Philadelphia Butterworth Heinemann; 2005 p. 237-50
-
(2005)
Principles of Treatment in Parkinson's Disease
, pp. 237-250
-
-
Stocchi, F.1
-
73
-
-
20444470602
-
Striatal deformities of the hand and foot in Parkinson's disease
-
Ashour R, Tintner R, Jankovic J. Striatal deformities of the hand and foot in Parkinson's disease. Lancet Neurol 2005;4:423-31
-
(2005)
Lancet Neurol
, vol.4
, pp. 423-431
-
-
Ashour, R.1
Tintner, R.2
Jankovic, J.3
-
74
-
-
0017681987
-
Neurosurgical treatment of the dyskinesias
-
Cooper IS. Neurosurgical treatment of the dyskinesias. Clin Neurosurg 1977;24:367-90
-
(1977)
Clin Neurosurg
, vol.24
, pp. 367-390
-
-
Cooper, I.S.1
-
75
-
-
23244440135
-
Camptocormia: Pathogenesis, classification, and response to therapy
-
Azher SN, Jankovic J. Camptocormia: pathogenesis, classification, and response to therapy. Neurology 2005;65:355-9
-
(2005)
Neurology
, vol.65
, pp. 355-359
-
-
Azher, S.N.1
Jankovic, J.2
-
76
-
-
0342699486
-
Relation between cholinesterase inhibitor and Pisa syndrome
-
Kwak YT, Han IW, Baik J, Koo MS. Relation between cholinesterase inhibitor and Pisa syndrome. Lancet 2000;355:2222
-
(2000)
Lancet
, vol.355
, pp. 2222
-
-
Kwak, Y.T.1
Han, I.W.2
Baik, J.3
Koo, M.S.4
-
79
-
-
0037334135
-
Intraarticular corticosteroids, supervised physiotherapy, or a combination of the two in the treatment of adhesive capsulitis of the shoulder: A placebo-controlled trial
-
Carette S, Moffet H, Tardif J, et al. Intraarticular corticosteroids, supervised physiotherapy, or a combination of the two in the treatment of adhesive capsulitis of the shoulder: a placebo-controlled trial. Arthritis Rheum 2003;48:829-38
-
(2003)
Arthritis Rheum
, vol.48
, pp. 829-838
-
-
Carette, S.1
Moffet, H.2
Tardif, J.3
-
80
-
-
0032494807
-
Effectiveness of corticosteroid injections versus physiotherapy for treatment of painful stiff shoulder in primary care: Randomised trial
-
Van Der Windt DA, Koes BW, Deville W, et al. Effectiveness of corticosteroid injections versus physiotherapy for treatment of painful stiff shoulder in primary care: randomised trial. BMJ 1998;317:1292-6
-
(1998)
BMJ
, vol.317
, pp. 1292-1296
-
-
Van Der Windt, D.A.1
Koes, B.W.2
Deville, W.3
-
81
-
-
33747865174
-
EFNS guidelines on the diagnosis and management of orthostatic hypotension
-
Lahrmann H, Cortelli P, Hilz M, et al. EFNS guidelines on the diagnosis and management of orthostatic hypotension. Eur J Neurol 2006;13:930-6
-
(2006)
Eur J Neurol
, vol.13
, pp. 930-936
-
-
Lahrmann, H.1
Cortelli, P.2
Hilz, M.3
-
82
-
-
12544257720
-
Guidelines on management (diagnosis and treatment) of syncope - update 2004
-
Brignole M, Alboni P, Benditt DG, et al. Guidelines on management (diagnosis and treatment) of syncope - update 2004. Europace 2004;6:467-537
-
(2004)
Europace
, vol.6
, pp. 467-537
-
-
Brignole, M.1
Alboni, P.2
Benditt, D.G.3
-
83
-
-
34748866218
-
Nonpharmacological treatment, fludrocortisone, and domperidone for orthostatic hypotension in Parkinson's disease
-
Schoffer KL, Henderson RD, O'Maley K, O'Sullivan JD. Nonpharmacological treatment, fludrocortisone, and domperidone for orthostatic hypotension in Parkinson's disease. Mov Disord 2007;22:1543-9
-
(2007)
Mov Disord
, vol.22
, pp. 1543-1549
-
-
Schoffer, K.L.1
Henderson, R.D.2
O'Maley, K.3
O'Sullivan, J.D.4
-
84
-
-
0037180460
-
Water drinking acutely improves orthostatic tolerance in healthy subjects
-
Schroeder C, Bush VE, Norcliffe LJ, et al. Water drinking acutely improves orthostatic tolerance in healthy subjects. Circulation 2002;106:2806-11
-
(2002)
Circulation
, vol.106
, pp. 2806-2811
-
-
Schroeder, C.1
Bush, V.E.2
Norcliffe, L.J.3
-
85
-
-
0033608269
-
A potent pressor response elicited by drinking water
-
Jordan J, Shannon JR, Grogan E, et al. A potent pressor response elicited by drinking water. Lancet 1999;353:723
-
(1999)
Lancet
, vol.353
, pp. 723
-
-
Jordan, J.1
Shannon, J.R.2
Grogan, E.3
-
86
-
-
33645931324
-
The patient with supine hypertension and orthostatic hypotension: A clinical dilemma
-
Naschitz JE, Slobodin G, Elias N, Rosner I. The patient with supine hypertension and orthostatic hypotension: a clinical dilemma. Poatgrad Med J 2006;82:246-53
-
Poatgrad Med
, vol.J 2006
, Issue.82
, pp. 246-253
-
-
Naschitz, J.E.1
Slobodin, G.2
Elias, N.3
Rosner, I.4
-
87
-
-
0142219814
-
Dysautonomia in Parkinson's disease: Neurocardiological abnormalities
-
Goldstein DS. Dysautonomia in Parkinson's disease: neurocardiological abnormalities. Lancet Neurol 2003;2:669-76
-
(2003)
Lancet Neurol
, vol.2
, pp. 669-676
-
-
Goldstein, D.S.1
-
88
-
-
33645739276
-
Pyridostigmine treatment trial in neurogenic orthostatic hypotension
-
Singer W, Sandroni P, Opfer-Gehrking TL, et al. Pyridostigmine treatment trial in neurogenic orthostatic hypotension. Arch Neurol 2006;63:513-8
-
(2006)
Arch Neurol
, vol.63
, pp. 513-518
-
-
Singer, W.1
Sandroni, P.2
Opfer-Gehrking, T.L.3
-
89
-
-
0024435720
-
Swallowing abnormalities and their response to treatment in Parkinson's disease
-
Bushmann M, Dobmeyer SM, Leeker L, Perlmutter JS. Swallowing abnormalities and their response to treatment in Parkinson's disease. Neurology 1989;39:1309-14
-
(1989)
Neurology
, vol.39
, pp. 1309-1314
-
-
Bushmann, M.1
Dobmeyer, S.M.2
Leeker, L.3
Perlmutter, J.S.4
-
91
-
-
0017809747
-
Evidence for a change in neurotransmitter affecting oesophageal motility in Parkinson's disease
-
Bramble MG, Cunliffe J, Dellipiani AW. Evidence for a change in neurotransmitter affecting oesophageal motility in Parkinson's disease. J Neurol Neurosurg Psychiatry 1978;41:709-12
-
(1978)
J Neurol Neurosurg Psychiatry
, vol.41
, pp. 709-712
-
-
Bramble, M.G.1
Cunliffe, J.2
Dellipiani, A.W.3
-
92
-
-
0024497156
-
Off-period belching due to a reversible disturbance of oesophageal motility in Parkinson's disease and its treatment with apomorphine
-
Kempster PA, Lees AJ, Crichton P, et al. Off-period belching due to a reversible disturbance of oesophageal motility in Parkinson's disease and its treatment with apomorphine. Mov Disord 1989;4:47-52
-
(1989)
Mov Disord
, vol.4
, pp. 47-52
-
-
Kempster, P.A.1
Lees, A.J.2
Crichton, P.3
-
93
-
-
0018819764
-
Interaction of levodopa and metoclopramide on gastric emptying
-
Berkowitz DM, McCallum RW. Interaction of levodopa and metoclopramide on gastric emptying. Clin Pharmacol Ther 1980;27:414-20
-
(1980)
Clin Pharmacol Ther
, vol.27
, pp. 414-420
-
-
Berkowitz, D.M.1
McCallum, R.W.2
-
94
-
-
0015374287
-
The effect of antacid administration on the absorption and metabolism of levodopa
-
Leon AS, Spiegel HE. The effect of antacid administration on the absorption and metabolism of levodopa. J Clin Pharmacol New Drugs 1972;12:263-7
-
(1972)
J Clin Pharmacol New Drugs
, vol.12
, pp. 263-267
-
-
Leon, A.S.1
Spiegel, H.E.2
-
96
-
-
0026688256
-
Clinical and pharmacokinetic effects of a diet rich in insoluble fiber on Parkinson disease
-
Astarloa R, Mena MA, Sanchez V, et al. Clinical and pharmacokinetic effects of a diet rich in insoluble fiber on Parkinson disease. Clin Neuropharmacol 1992;15:375-80
-
(1992)
Clin Neuropharmacol
, vol.15
, pp. 375-380
-
-
Astarloa, R.1
Mena, M.A.2
Sanchez, V.3
-
97
-
-
0024416844
-
Anal sphincter dysfunction in Parkinson's disease
-
Mathers SE, Kempster PA, Law PJ, et al. Anal sphincter dysfunction in Parkinson's disease. Arch Neurol 1989;46:1061-4
-
(1989)
Arch Neurol
, vol.46
, pp. 1061-1064
-
-
Mathers, S.E.1
Kempster, P.A.2
Law, P.J.3
-
98
-
-
0024207550
-
Role of subcutaneous apomorphine in parkinsonian voiding dysfunction
-
Christmas TJ, Kempster PA, Chapple CR, et al. Role of subcutaneous apomorphine in parkinsonian voiding dysfunction. Lancet 1988;2:1451-3
-
(1988)
Lancet
, vol.2
, pp. 1451-1453
-
-
Christmas, T.J.1
Kempster, P.A.2
Chapple, C.R.3
|